Nashik firm gets US FDA’s ‘breakthrough designation’ for breast cancer detection blood test
A Nashik-based cancer research company has announced that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Designation’ for its blood test to detect early-stage breast cancer. The blood test uses proprietary technology developed by Datar Cancer Genetics to detect circulating tumour cells and clusters specific to breast cancer with very high accuracy. Data from clinical trials has shown that the test can detect stage 0 (DCIS) and stage I breast cancers with accuracy of over 99 per cent without any false positives.
Comments